Results obtained in the LifEscozul™ Protocol in patient Luis Altamirano.
In this interview, for the LifEscozul Protocol™ (Escozul, poison of the scorpionblue, blue scorpion) we talked about Luis.
Luis entered the LifEscozul™ protocol in 2017. Luis had undergone surgery for colon cancer (specifically a well-differentiated adenocarcinoma), which after surgery in 2014, metastasized to the liver for the first time in October 2016, with involvement of segment VII, left lobe, which was surgically removed (segmentectomy), and again metastasized to the liver in January 2017, with 3 tumor lesions in the right lobe, between 0.5 and 1.5cm in size.
Although Luis was also treated with chemotherapy his use was not continuous, due to variations in the availability of chemotherapy drugs in his country's healthcare system. After he started withLifEscozul™ , Luis went two months without chemotherapy, consuming only LifEscozul™.
After 3 months of continuous treatment with LifEscozul™, we received both an ultrasound and a CT scan of Luis' abdomen and pelvis, which showed no lesions in the liver.
The 3 tumor lesions previously observed had disappeared.
The new CT scan performed at the end of September confirms that there is no evidence of disease.
This interview was conducted by Biologist Ariel Portal for the Protocol LifEscozul™ (Escozul, blue scorpion venom, blue scorpion venom).
Luis was treated with LifEscozul™ (protein active ingredient) with periodic controls and progressive dose increases.
For any questions please write to email@example.com or fill out the form.
The LifEscozul Group™ continues with this interview a cycle of interviews with our oldest patients within the LifEscozul Protocol™ ( Escozul, blue scorpion venom, blue scorpion).
LifEscozul™ is a product with a registered trademark in the USA and Ecuador and in the process of registration in more than 20 countries. It has been developed by Cuban doctors and scientists based on the antitumor active ingredient extracted from blue scorpion venom (Escozul).